High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. 1993

T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, NJ 8543-4500.

An isocratic high-performance liquid chromatographic method has been developed and validated for the quantitative determination of paclitaxel (Taxol), a novel antimitotic, anticancer agent, in human plasma. The analysis required 0.5 ml of plasma, and was accomplished by detection of the UV absorbance of paclitaxel at 227 nm following extraction and concentration. The method involved extraction of paclitaxel from plasma, buffered with 0.5 ml of 0.2 M ammonium acetate (pH 5.0), onto 1-ml cyano Bond Elut columns. The eluent was evaporated under nitrogen and low heat, and reconstituted with the mobile phase, acetonitrile-methanol-water (4:1:5, v/v/v) containing 0.01 M ammonium acetate (pH 5.0). The samples were chromatographed on a reversed-phase octyl 5 microns column. The retention time of paclitaxel was 10 min. The validated quantitation range of the method was 10-1000 ng/ml (0.012-1.17 microM) of paclitaxel in plasma. Standard curve correlation coefficients of 0.995 or greater were obtained during validation experiments and analysis of clinical study samples. The observed recovery for paclitaxel was 83%. Epitaxol, a biologically active stereoisomer, and baccatin III, a degradation product, were also chromatographically separated from taxol by this assay. The method was applied to samples from a clinical study of paclitaxel in cancer patients, providing a pharmacokinetic profiling of paclitaxel.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011786 Quality Control A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed) Control, Quality,Controls, Quality,Quality Controls
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005615 Freezing Liquids transforming into solids by the removal of heat. Melting
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris

Related Publications

T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
February 1995, Journal of chromatography. B, Biomedical applications,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
June 1997, Therapeutic drug monitoring,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
October 1983, Journal of chromatography,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
January 1998, Rapid communications in mass spectrometry : RCM,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
May 1994, Journal of chromatography. B, Biomedical applications,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
November 1990, Analytical biochemistry,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
June 1988, Archiv der Pharmazie,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
April 1990, Journal of chromatography,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
January 1981, Journal of chromatography,
T A Willey, and E J Bekos, and R C Gaver, and G F Duncan, and L K Tay, and J H Beijnen, and R H Farmen
August 1990, Journal of chromatography,
Copied contents to your clipboard!